background
overal
gastric
cancer
surviv
remain
poor
mainli
reliabl
method
identifi
highli
curabl
earli
stage
diseas
multiprotein
profil
gastric
fluid
obtain
anatom
site
patholog
could
reveal
diagnost
proteom
fingerprint
method
protein
profil
gener
gastric
fluid
sampl
gastric
cancer
benign
gastritid
patient
undergo
elect
clinicallyind
gastroscopi
use
surfaceenhanc
laser
desorpt
ioniz
timeofflight
mass
spectrometri
multipl
proteinchip
array
proteom
featur
compar
signific
analysi
microarray
algorithm
twoway
hierarch
cluster
second
blind
sampl
set
gastric
cancer
clinic
benign
gastritid
use
valid
signific
analysyi
microarray
proteom
featur
upregul
downregul
gastric
cancer
sampl
p
multimark
cluster
show
two
distinct
proteom
profil
independ
age
ethnic
eighteen
cancer
sampl
cluster
togeth
sensit
noncanc
sampl
cluster
second
group
nine
noncanc
sampl
cluster
cancer
sampl
includ
premalign
lesion
adenomat
polyp
intestin
metaplasia
valid
use
second
sampl
set
show
sensit
specif
respect
posit
predict
valu
combin
data
select
peptid
sequenc
identifi
pepsinogen
c
pepsin
activ
peptid
significantli
downregul
alphadefensin
significantli
upregul
simpl
reproduc
multimark
proteom
assay
could
supplement
clinic
gastroscop
evalu
symptomat
patient
enhanc
diagnost
accuraci
gastric
cancer
premalign
lesion
unlik
common
cancer
prognosi
gastric
cancer
patient
poor
improv
littl
past
sever
decad
fiveyear
surviv
rate
gastric
cancer
consider
lower
major
cancer
except
cancer
liver
pancrea
esophagu
given
earli
stage
gastric
cancer
much
better
prognosi
year
surviv
approxim
advanc
gastric
cancer
surviv
global
mortal
gastric
cancer
ought
decreas
substanti
measur
result
downstag
tumor
time
initi
diagnosi
although
gastroscopi
gold
standard
gastric
cancer
diagnosi
accuraci
high
benign
gastric
diseas
peptic
ulcer
especi
geograph
region
low
intermedi
gastric
cancer
preval
percentag
miss
cancer
diagnosi
report
even
insignific
even
japan
fals
neg
rate
report
data
consist
posit
predict
valu
endoscop
diagnosi
gastric
cancer
differ
center
although
proport
miss
diagnos
appear
small
absolut
number
patient
deni
benefit
diagnosi
curabl
stage
neglig
even
modestli
low
fals
posit
diagnost
rate
gastric
cancer
would
miss
one
low
preval
countri
alon
usa
singl
year
endoscop
assess
frequent
includ
mucos
biopsi
clinic
standard
either
optim
number
biopsi
anatom
region
sampl
commonli
cite
recommend
take
least
seven
biopsi
correctli
diagnos
gastric
cancer
studi
howev
fulli
lesion
subsequ
shown
malign
consid
benign
endoscopi
thu
endoscop
mucos
examin
suffer
interobserv
variat
suboptim
correl
histopatholog
difficulti
detect
submucos
cancer
unimped
visual
anatom
subregion
eg
previou
gastric
surgeri
gastric
fluid
consist
mixtur
secret
solubl
exfoli
cellular
protein
entir
gastric
mucosa
includ
region
adequ
assess
fibreopt
gastroscopi
therefor
reason
proteom
profil
gastric
fluid
usual
regard
wast
byproduct
gastroscop
examin
could
use
supplement
convent
clinic
evalu
provid
molecular
biopsi
effect
sampl
entir
gastric
mucosa
especi
protein
detect
techniqu
mass
spectrometri
highli
sensit
perform
cours
clinic
indic
gastroscopi
obtain
gastric
fluid
increas
invas
procedur
unlik
plasma
proteom
gastric
fluid
proteom
like
less
complex
enrich
diseasespecif
biomark
gener
directli
diseas
site
biomark
even
present
plasma
may
dilut
beyond
limit
detect
admix
abund
system
protein
reflect
concurr
pathophysiolog
condit
eg
comorbid
diseas
rather
anatom
sitespecif
diseas
investig
novel
approach
develop
biomark
gastric
cancer
profil
solubl
secret
peptid
present
endoscop
aspir
gastric
fluid
protein
extract
exfoli
epitheli
cell
also
recov
endoscopi
surfaceenhanc
laser
desorptionion
timeofflight
seldi
tof
mass
spectrometri
result
suggest
multipl
protein
biomark
organspecif
sourc
ie
gastric
fluid
gener
distinct
gastric
cancer
signatur
merit
develop
tool
improv
diagnost
accuraci
gastroscopi
potenti
detect
earli
stage
gastric
cancer
premalign
lesion
intestin
metaplasia
dysplasia
gastric
fluid
obtain
gastroscopi
overnight
fast
patient
seen
singapor
gener
hospit
studi
protocol
approv
ethic
committe
singapor
gener
hospit
conform
provis
declar
helsinki
indic
gastroscopi
sole
clinic
independ
studi
initi
analysi
perform
train
set
sampl
histolog
proven
gastric
adenocarcinoma
intestin
type
diffus
type
mix
type
indetermin
sampl
patient
clinic
benign
gastric
condit
mean
age
gastric
cancer
patient
male
femal
chines
indian
year
distribut
american
joint
committe
cancer
ajcc
clinic
stage
stage
patient
stage
patient
stage
ii
patient
stage
iii
patient
stage
iv
patient
mean
age
patient
benign
gastric
condit
male
femal
chines
malay
indian
year
clinic
diagnos
endoscopi
noncanc
patient
normal
antral
gastriti
gastriti
ulcer
hiatal
hernia
hyperplast
polyp
barrett
esophagu
fundic
scar
adenomat
polyp
classif
algorithm
develop
train
set
test
blind
analysi
valid
set
consist
anoth
histolog
confirm
gastric
adenocarcinoma
intestin
type
diffus
type
mix
type
indetermin
neuroendocrin
clinic
benign
gastric
sampl
mean
age
gastric
cancer
patient
male
femal
chines
malay
year
distribut
ajcc
clinic
stage
stage
patient
stage
ii
patient
stage
iii
patient
stage
iv
patient
one
patient
valid
set
declin
investig
could
stage
mean
age
noncanc
patient
male
femal
chines
indian
malay
year
clinic
diagnos
gastroscopi
noncanc
patient
gastriti
fundic
gland
polyp
acut
gastric
ulcer
duoden
hiatal
hernia
normal
none
gastric
cancer
patient
receiv
form
cancer
treatment
time
gastroscopi
take
train
valid
case
togeth
patient
gastric
cancer
benign
gastric
condit
respect
posit
h
pylori
differ
signific
fisher
exact
test
p
valu
gastric
fluid
aspir
steril
contain
commenc
endoscopi
assign
anonymis
code
immedi
place
ice
bloodor
bilestain
sampl
reject
clinic
suspici
mucos
lesion
biopsi
discret
endoscopist
gastric
fluid
centrifug
g
minut
supernat
centrifug
g
minut
pellet
centrifug
combin
highspe
supernat
store
separ
pellet
gastric
fluid
pellet
resuspend
moll
guanidin
thiocyan
gl
octyl
glucopyranosid
moll
hepe
ph
moll
urea
gl
chap
mmoll
trishcl
ph
vortex
minut
centrifug
g
minut
extract
appli
proteinchip
array
describ
retent
map
gener
individu
protein
display
separ
peak
basi
mass
charg
ratio
data
proteom
spectra
analyz
ciphergen
express
data
manag
softwar
pattern
track
twoway
hierarch
cluster
algorithm
align
peak
signal
nois
ratio
normal
total
ion
current
proteom
featur
analyz
use
signific
analysi
microarray
sam
softwar
stanford
univers
packag
design
address
problem
specif
microarray
data
analysi
signal
nois
ratio
varianc
differ
gene
gene
larg
number
data
point
small
number
sampl
found
applic
proteom
data
analysi
well
algorithm
softwar
describ
tusher
et
al
brief
defin
metric
call
rel
differ
measur
differ
two
group
data
place
p
valu
employ
variat
bootstrap
method
repeatedli
divid
given
data
set
spectra
contain
proteom
featur
studi
randomli
two
group
calcul
rel
differ
permut
number
permut
set
studi
softwar
comput
rel
differ
valu
proteom
featur
rel
differ
particular
group
interest
observ
rel
differ
compar
averag
rel
differ
permut
expect
rel
differ
featur
featur
judg
upor
downregul
accord
whether
observ
rel
differ
greater
smaller
expect
rel
differ
threshold
softwar
estim
fals
discoveri
rate
also
defin
refer
threshold
valu
provid
indirect
mean
set
cutoff
marker
identifi
method
statist
signific
fals
discoveri
rate
set
less
studi
valid
marker
identifi
sam
second
batch
blind
sampl
ad
data
set
hierarch
cluster
use
ciphergen
express
data
manag
softwar
known
sampl
use
sam
select
marker
expect
perform
well
cluster
blind
sampl
includ
test
well
marker
gener
unknown
sampl
result
cluster
simpli
compar
true
ident
sampl
advanc
classif
method
softwar
use
valid
gastric
fluid
protein
fraction
anion
exchang
chromatographi
q
hyperd
ciphergen
biosystem
inc
use
stepwis
chang
ph
elut
protein
mmoll
trishcl
gl
octyl
glucopyranosid
ph
eluant
purifi
cation
exchang
array
use
mmoll
sodium
acet
gl
octyl
glucopyranosid
ph
bind
wash
buffer
addit
acid
energi
absorb
molecul
ciphergen
biosystem
inc
retain
protein
analyz
pbsii
qtof
watersmicromass
equip
proteinchip
interfac
pci
ciphergen
biosystem
inc
protein
character
msm
fragment
identif
done
databas
search
mascot
matrix
scienc
ltd
london
uk
perform
third
set
gastric
fluid
sampl
taken
benign
gastric
gastric
cancer
patient
freshli
collect
sampl
process
remov
solid
debri
concentr
protein
content
follow
ad
phenylmethanesulfonyl
fluorid
final
concentr
mm
sampl
centrifug
minut
g
proteas
inhibitor
complet
roch
appli
scienc
indianapoli
usa
ad
supernat
follow
centrifug
membran
filtrat
g
amicon
centrifug
filter
devic
nomin
molecular
weight
limit
millipor
billerica
usa
sampl
reduc
origin
volum
total
protein
concentr
determin
quant
kit
amersham
bioscienc
pisctaway
nj
usa
pepsinogen
c
alphadefensin
concentr
determin
enzymelink
immunoassay
elisa
use
kit
alpco
diagnost
salem
nh
usa
hycult
biotechnolog
bv
uden
netherland
respect
process
sampl
assay
duplic
pepsinogen
c
defensin
level
use
supplier
protocol
sampl
pepsinogen
c
assay
predilut
concentr
pepsinogen
c
alphadefensin
deriv
refer
respect
standard
curv
express
ng
pepsinogen
c
pg
defensin
per
microgram
total
gastric
fluid
protein
presenc
h
pylori
stomach
tissu
identifi
visual
spiral
microorgan
histolog
section
andor
immunohistochemistri
fourmicron
tissu
section
dewax
xylen
decreas
grade
ethanol
antigen
retriev
heat
citrat
buffer
ph
primari
antibodi
h
pylori
dilut
dako
glostrup
denmark
follow
secondari
antibodi
polym
link
envis
chem
mate
dako
visual
use
diaminobenzidin
chromogen
multipl
upor
downregul
protein
biomark
gastric
cancer
discov
gastric
fluid
repres
proteom
map
gastric
fluid
shown
figur
gel
view
mass
spectrum
show
gastric
fluid
protein
select
bound
immobil
copper
ii
metal
ion
molecular
weight
rang
da
da
signific
protein
marker
found
downregul
cancer
gastric
fluid
p
indic
arrow
repres
proteom
map
gastric
fluid
pellet
extract
shown
figur
protein
select
bound
cation
exchang
array
surfac
signific
protein
marker
found
upor
downregul
gastric
cancer
fluid
pellet
p
indic
arrow
averag
cv
coeffici
variat
cumul
major
gastric
fluid
peak
per
spectrum
n
immobil
copper
ii
proteinchip
array
cation
exchang
array
anion
exchang
array
hydrophob
interact
chip
cv
valu
line
reproduc
assess
seldi
literatur
sam
analysi
proteom
featur
total
number
featur
averag
number
per
retent
map
gastric
fluid
pellet
extract
proteom
featur
found
significantli
downregul
gastric
cancer
proteom
featur
significantli
upregul
gastric
cancer
data
differ
condit
eg
fluid
pellet
well
differ
surfac
simpli
aggreg
togeth
distinct
featur
sam
marker
report
sam
pellet
supernat
fraction
manual
identifi
repres
list
deem
biolog
signific
significantli
downregul
marker
includ
da
significantli
upregul
marker
includ
da
signific
marker
discov
imaccopp
ii
follow
base
significantli
differ
proteom
featur
addit
file
twoway
hierarch
cluster
analysi
twodimension
complet
linkag
perform
gastric
cancer
case
cluster
togeth
form
distinct
group
figur
addit
file
princip
compon
analysi
data
also
reveal
cancer
benign
sampl
could
well
separ
two
group
fals
neg
repres
duplic
analysi
case
fals
posit
respect
figur
one
gastric
cancer
fluid
sampl
case
stage
poorli
differenti
gastric
adenocarcinoma
cluster
among
noncanc
sampl
earli
stage
stage
patient
correctli
cluster
sampl
patient
stage
ii
iv
gastric
cancer
give
overal
diagnost
sensit
gastric
cancer
patient
train
set
nine
noncanc
sampl
train
set
cluster
cancer
sampl
specif
dysplast
adenomat
polyp
precancer
lesion
among
patient
clinic
direct
biopsi
reveal
intestin
metaplasia
patient
eight
noncanc
patient
whose
gastric
fluid
protein
profil
cluster
normal
group
also
clinic
direct
mucos
biopsi
show
intestin
metaplasia
patient
review
consecut
gastric
biopsi
perform
indic
show
overal
preval
intestin
metaplasia
singapor
gener
hospit
studi
period
contrast
preval
least
intestin
metaplasia
among
clinic
benign
case
whose
proteom
profil
cluster
close
gastric
cancer
case
normal
consist
intestin
metaplasia
intermedi
state
transit
normal
gastric
epithelium
gastric
adenocarcinoma
accur
identif
intestin
metaplasia
endoscopi
known
inaccur
thu
gastric
cancertyp
proteom
fingerprint
possibl
sensit
indic
presenc
premalign
lesion
among
patient
clinic
diagnos
benign
gastric
disord
gastric
cancer
patient
train
set
significantli
older
mean
age
year
patient
benign
gastric
condit
mean
age
p
express
differ
map
gastric
fluid
copper
ii
immobil
metal
affin
captur
proteinchip
array
figur
express
differ
map
gastric
fluid
copper
ii
immobil
metal
affin
captur
proteinchip
array
arrow
indic
protein
biomark
significantli
differ
express
level
two
group
sampl
address
possibl
protein
profil
relat
age
ethnic
reanalyz
data
subset
chines
patient
year
age
result
cancer
misclassifi
tumor
misclassifi
cancer
analyz
sensit
control
misclassifi
control
among
misclassifi
benign
case
specif
next
test
actual
perform
proteom
profil
distinguish
cancer
benign
sampl
second
seri
blind
gastric
fluid
pellet
extract
sampl
gastric
cancer
benign
gastric
disord
addit
file
twentyon
gastric
cancer
correctli
identifi
sensit
benign
sampl
wrongli
classifi
specif
figur
select
proteom
marker
base
signific
score
determin
sam
semipurifi
proteinchip
array
identifi
directli
spot
collisioninduc
dissoci
sequenc
figur
sever
significantli
downregul
marker
cancer
patient
shown
figur
da
da
da
da
identifi
pepsinogen
c
pepsin
activ
peptid
fragment
tabl
upregul
triplet
marker
cancer
patient
shown
figur
addit
file
identifi
alpha
intens
scatter
plot
show
highli
signific
differ
mean
intens
defensin
pepsin
fragment
benign
control
gastric
cancer
fluid
sampl
p
respect
figur
use
elisa
specif
pepsinogen
c
confirm
significantli
lower
concentr
gastric
cancer
fluid
total
protein
mean
sem
n
compar
benign
sampl
total
express
differ
map
gastric
fluid
pellet
extract
cation
exchang
proteinchip
array
figur
express
differ
map
gastric
fluid
pellet
extract
cation
exchang
proteinchip
array
arrow
indic
protein
biomark
significantli
differ
express
level
two
group
sampl
protein
n
third
sampl
set
p
student
unpair
twotail
test
elisa
perform
sampl
set
defensin
level
show
higher
concentr
gastric
cancer
sampl
total
protein
mean
sem
n
benign
sampl
total
protein
mean
sem
n
p
student
test
data
suggest
spectral
profil
unfraction
gastric
fluid
could
use
adjunct
cancer
diagnosi
detect
earli
stage
diseas
combin
clinic
gastroscopi
recent
attempt
identifi
protein
biomark
gastric
cancer
investig
serum
tissu
increasingli
use
mass
spectrometri
older
report
serolog
express
differ
map
gastric
fluid
pellet
extract
protein
train
set
sampl
four
proteinchip
array
display
twoway
hierarch
cluster
assay
individu
known
tumor
marker
eg
cea
ca
ca
gener
low
sensit
moreov
substanti
crossposit
tumor
marker
nongastr
cancer
eg
rais
cea
level
common
colorect
cancer
cholangiocarcinoma
pancreat
carcinoma
even
healthi
control
surprisingli
serum
tumor
marker
establish
role
gastric
cancer
diagnosi
screen
although
may
serv
prognost
indic
earli
marker
recurr
diseas
follow
gastrectomi
chose
examin
proteom
profil
gastric
fluid
diseas
biomark
seem
like
perturb
gastric
protein
secret
malign
premalign
state
coupl
possibl
presenc
exfoli
cancer
cell
could
gener
distinct
proteom
profil
search
serum
biomark
sever
group
investig
diagnost
util
known
tumor
marker
gastric
juic
neither
cea
ca
posit
gastric
fluid
demonstr
diagnost
accuraci
antitrypsin
gastric
juic
recent
report
gastric
cancer
biomark
express
differ
map
gastric
fluid
pellet
extract
protein
valid
set
sampl
four
proteinchip
array
display
twoway
hierarch
cluster
figur
express
differ
map
gastric
fluid
pellet
extract
protein
valid
set
sampl
four
proteinchip
array
display
twoway
hierarch
cluster
signific
proteom
featur
display
horizont
intens
red
green
colour
indic
degre
rel
protein
level
higher
lower
median
valu
patient
case
present
vertic
gastric
cancer
patient
tightli
cluster
togeth
approach
develop
sensit
method
gastric
cancer
diagnosi
differ
previou
studi
three
way
first
chose
biolog
sampl
organspecif
ie
endoscop
aspir
gastric
fluid
rather
system
ie
serum
reason
molecular
featur
would
like
diseasespecif
second
mass
spectrometri
enabl
us
take
unbias
discoverybas
approach
third
data
gener
profil
multipl
proteom
marker
increasingli
regard
higher
sensit
specif
singl
tumor
marker
gastric
cancer
combin
even
tumor
marker
achiev
better
diagnost
accuraci
compar
singl
marker
alon
protein
fingerprint
gastric
fluid
gastric
cancer
patient
show
total
proteom
featur
significantli
upor
downregul
addit
file
two
promin
marker
select
identif
msm
pepsinogen
pepsinogen
c
activ
peptid
downregul
gastric
fluid
remov
stomach
histolog
confirm
adenocarcinoma
studi
cryostat
section
gastric
cancer
also
report
signific
downregul
pepsinogen
c
identifi
msm
tumor
tissu
reduc
pepsinogen
level
blood
tissu
wellknown
consequ
multifoc
chronic
atroph
gastriti
histopatholog
condit
increas
risk
highresolut
mass
spectrum
fraction
gastric
fluid
protein
proteinchip
array
obtain
qtof
equip
interfac
figur
highresolut
mass
spectrum
fraction
gastric
fluid
protein
proteinchip
array
obtain
qtof
equip
interfac
box
peak
subject
fragment
analysi
collisioninduc
dissoci
msm
develop
intestinaltyp
gastric
cancer
howev
chronic
atroph
gastriti
gastric
cancer
prospect
longitudin
studi
determin
patient
lesion
progress
gastric
cancer
anoth
prospect
seri
sever
chronic
atroph
gastriti
actual
regress
less
advanc
lesion
follow
year
henc
although
serum
pepsinogen
level
intens
investig
costeffect
serolog
biopsi
noninvas
gastric
cancer
screen
low
posit
predict
valu
gener
popul
studi
select
patient
identifi
promin
upregul
marker
alphadefensin
immunohistochem
stain
gastric
adenocarcinoma
tissu
show
alphadefensin
express
restrict
infiltr
neutrophil
absent
normal
malign
gastric
epitheli
cell
data
shown
alphadefensin
overexpress
intratumor
neutrophil
also
report
oral
carcinoma
peptid
sequenc
immunohistochemistri
associ
defensin
express
cancer
consist
role
chronic
inflamm
oncogenesi
express
alphadefensin
higher
colorect
cancer
normal
colon
correl
tumor
invas
bladder
cancer
use
seldi
tof
mass
spectrometri
alphadefensin
among
five
promin
protein
urin
sampl
patient
transit
cell
bladder
cancer
neutrophil
defensin
also
identifi
proteom
signatur
ovarian
breast
cancer
data
show
protein
fingerprint
gastric
fluid
achiev
high
sensit
specif
reli
singl
marker
multivari
analysi
multimark
panel
gastric
fluid
exfoli
cellular
proteom
reveal
composit
pattern
upand
downregul
multipl
compon
gener
highli
specif
sensit
diagnost
method
gastric
cancer
includ
earli
stage
diseas
protein
profil
studi
independ
age
ethnic
perform
well
correctli
identifi
whether
gastric
fluid
obtain
malign
benign
sourc
sensit
specif
test
independ
blind
sampl
combin
data
train
valid
sampl
set
gastric
cancer
proteom
signatur
posit
predict
valu
previou
biomark
discoveri
studi
focus
limit
number
marker
approach
diagnost
accuraci
studi
reli
singl
biomark
sever
disadvantag
individu
marker
gener
power
classifi
diseas
healthi
control
biofluid
studi
bladder
cancer
marker
use
seldi
tof
mass
spectrometri
found
detect
rate
singl
marker
significantli
improv
biomark
combin
cluster
analysi
confirm
experi
thu
although
mean
albumin
level
gastric
cancer
fluid
significantli
differ
control
p
cancer
patient
train
set
show
elev
data
shown
wherea
transferrin
level
upregul
even
smaller
number
patient
significantli
differ
gener
patient
popul
p
data
shown
furthermor
mani
cancer
share
marker
eg
cea
transferrin
highresolut
mass
spectrum
gastric
fluid
protein
proteinchip
array
obtain
qtof
equip
interfac
figur
highresolut
mass
spectrum
gastric
fluid
protein
proteinchip
array
obtain
qtof
equip
interfac
figur
show
upregul
triplet
marker
gastric
cancer
pleas
see
addit
file
full
imag
highli
inform
protein
profil
biomark
discoveri
gener
high
throughput
analysi
gastric
fluid
exfoli
cellular
proteom
use
small
sampl
volum
simpl
sampl
process
identif
pepsinogen
c
among
promin
downregul
marker
gastric
cancer
fluid
sampl
strengthen
biolog
plausibl
proteom
signatur
report
gastric
cancer
diagnosi
futur
larg
cohort
studi
need
confirm
result
particularli
import
incorpor
multipl
mucos
biopsi
standard
site
close
follow
patient
clinic
benign
gastric
disord
whose
proteom
profil
cancerlik
given
high
cur
potenti
earli
stage
gastric
cancer
document
fals
neg
gastroscop
diagnosi
expens
endoscop
surveil
gastric
ulcer
test
provid
pangastr
molecular
biopsi
could
clinic
use
supplement
convent
gastroscopi
proteom
signatur
distinguish
benign
malign
disord
identifi
earli
stage
cancer
premalign
gastric
lesion
high
sensit
specif
could
make
signific
contribut
reduc
mortal
second
common
caus
global
cancer
death
